Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Conversely, this group demonstrated increased sensitivity to cholecalciferol, olaparib, PRL-3 inhibitor, bicalutamide, and so on, which provides a reliable idea for future precise drug treatment of liver cancer (Fig. 3).
Source: Drug sensitivity analysis of SMARCAL1 in liver cancer. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The Cancer Genome Atlas (TCGA)-Liver Hepatocellular Carcinoma (LIHC) cohort data were downloaded from TCGA database, and the RNAseq and corresponding clinical data of patients were extracted.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Integrated multi-omics analysis reveals that SMARCAL1 serves as an immune related prognostic marker and promotes liver cancer growth
Study design awaiting verification · International Journal of Surgery (London, England) · 2026
Original publication title
Integrated multi-omics analysis reveals that SMARCAL1 serves as an immune related prognostic marker and promotes liver cancer growth
Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To illustrate the potential role of SMARCAL1 in malignancy, immune regulation, and related pathway in liver cancer.
Source: Objective:Abstract: What methods does the paper describe?
In our study, we examined the expression patterns, clinical features, and survival analysis from The Cancer Genome Atlas and GEO datasets. Immunedeconv package was employed for evaluating the association between the immune infiltration components and SMARCAL1 expression. Knockdown experiment was performed to examine the impacts of SMARCAL1 on cell viability, apoptosis, and classical Hippo-YAP pathway. Meanwhile, the association between SMARCAL1 expression and drug sensitivity was constructed through CTRP, PRISM, and GDSC databases. Finally, we also discovered novel inhibitors of SMARCAL1 activity against liver cancer and YAP activity through virtual screening and western blot assay.
Source: Methods:Abstract: Results
SMARCAL1 exhibited increased expression in liver cancer (LIHC) and was linked to unfavorable outcomes for patients. SMARCAL1 expression was associated with specific clinical features, drug sensitivity, and immune microenvironment characteristics. Additionally, SMARCAL1 was closely related to the activity of Hippo-YAP pathway. Finally, deferoxamine mesylate and its parent compound deferoxamine were identified as candidate inhibitors of SMARCAL1 activity, showing significant ability to inhibit proliferation and the downstream protein YAP1.
Source: Results:Abstract: Conclusion
Targeting SMARCAL1 could be a promising strategy for liver cancer treatment.
Source: Conclusion:Authors’ abstract
Objective:
To illustrate the potential role of SMARCAL1 in malignancy, immune regulation, and related pathway in liver cancer.
Methods:
In our study, we examined the expression patterns, clinical features, and survival analysis from The Cancer Genome Atlas and GEO datasets. Immunedeconv package was employed for evaluating the association between the immune infiltration components and SMARCAL1 expression. Knockdown experiment was performed to examine the impacts of SMARCAL1 on cell viability, apoptosis, and classical Hippo-YAP pathway. Meanwhile, the association between SMARCAL1 expression and drug sensitivity was constructed through CTRP, PRISM, and GDSC databases. Finally, we also discovered novel inhibitors of SMARCAL1 activity against liver cancer and YAP activity through virtual screening and western blot assay.
Results:
SMARCAL1 exhibited increased expression in liver cancer (LIHC) and was linked to unfavorable outcomes for patients. SMARCAL1 expression was associated with specific clinical features, drug sensitivity, and immune microenvironment characteristics. Additionally, SMARCAL1 was closely related to the activity of Hippo-YAP pathway. Finally, deferoxamine mesylate and its parent compound deferoxamine were identified as candidate inhibitors of SMARCAL1 activity, showing significant ability to inhibit proliferation and the downstream protein YAP1.
Conclusion:
Targeting SMARCAL1 could be a promising strategy for liver cancer treatment.
Publication and source details
Original title: Integrated multi-omics analysis reveals that SMARCAL1 serves as an immune related prognostic marker and promotes liver cancer growth
Tingting Huang; Meng Tang; Qiulin Tang; Di Ye; Jiayu Wang; Yichun Duan; Chenliang Zhang; Feng Bi
International Journal of Surgery (London, England) · 2026
* Corresponding authors. Address: Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. Tel.: +86-15928448662. E-mail: zhangchenliang@wchscu.edu.cn (C. Zhang); Tel.: +86-18980601771. E-mail: bifeng@scu.edu.cn (F. Bi).Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc.2026https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T01:07:03.493317+00:00
DOI: 10.1097/js9.0000000000004567 · PMC13105517